HER2 testing recommendations in the UK: dual- or single-colour in-situ hybridisation?
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
- Correspondence to Cathy B Moelans, Department of Pathology (H04.310), UMC Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands;
Contributors CBM and PJvD drafted the manuscript.
- Accepted 27 September 2011
- Published Online First 26 October 2011
- Breast cancer
- cancer research
- image analysis
- comparative genomic hybridisation
- digital pathology
- cell cycle regulation
- breast pathology
We have read with great interest the article by Bartlett et al on HER2 testing recommendations in the UK.1 The authors have discussed a number of important issues related to current diagnostic HER2 in situ hybridisation (ISH) testing and interpretation. Advice is given on relevant methodological and interpretation questions such as the need for centralisation, trained staff, quality control and the handling of referral tissue samples. However, in their discussion on the choice of ISH methods, the authors state quite firmly that they no longer recommend the use of …